EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 145 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Load more HOT NEWS Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored Pregnancy is Safe After Early Breast Cancer in Young Women with... Coming Soon: Medicare Drug Price Negotiations
